PMID: 9432405Mar 1, 1996Paper

A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer

Respirology : Official Journal of the Asian Pacific Society of Respirology
M MasutaniT Horie

Abstract

A randomized trial of chemotherapy in 105 patients with advanced and metastatic non-small-cell lung cancer (NCSLC) was conducted in order to compare the effect of the additional drug mitomycin C (PVM) or ifosfamide (PVI), to the combination of cisplatin plus vindesine (PV). An objective response rate was observed in 42.8% of the patients treated with PVM, 42.4% with PVI and 28.6% with PV and these response rates were not statistically significant (P > 0.20). No patient achieved the complete response with either of the three regimens. Comparison of the median response durations among the three regimens showed an advantage of PVI over PVM (P < 0.02) and PV (P < 0.05). The median survival times (MST) were similar for all three regimens (PVM, 33.5; PVI, 40.0 and PV, 36.5 weeks); moreover, the difference in survival time between the three regimens of responders was not statistically significant. The univariate analysis showed that significant predictors of survival were performance status (PS) zero (P = 0.0002), limited disease (P = 0.004), no previous weight loss (P = 0.01) and normal serum albumin (P = 0.016), and in multivariate analysis by a stepwise Cox proportional hazard model, these were PS zero (a hazard ratio of 2.3, P = 0...Continue Reading

References

Jan 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M FukuokaN Masuda
Feb 20, 1992·The New England Journal of Medicine·C Schaake-KoningA Nijs
Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T ShinkaiN Saijo
Jan 1, 1986·Cancer Chemotherapy and Pharmacology·P DringsH G Manke
Mar 1, 1971·The Journal of Hygiene·P Armitage
Apr 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M González BarónI de la Gándara
Mar 3, 1993·Journal of the National Cancer Institute·W K MurphyM N Raber
Feb 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T J LynchE Frei

❮ Previous
Next ❯

Citations

Apr 1, 1998·The Australian & New Zealand Journal of Obstetrics & Gynaecology·N TebbuttJ F Bishop
Mar 16, 2001·Expert Opinion on Pharmacotherapy·I Sekine, N Saijo
Dec 24, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David G PfisterUNKNOWN American Society of Clinical Oncology
Aug 16, 2000·Scandinavian Journal of Clinical and Laboratory Investigation·J Watine
Apr 20, 2012·The Cochrane Database of Systematic Reviews·Catherine DelbaldoJean Pierre Pignon
Aug 1, 1997·Protein Science : a Publication of the Protein Society·R L Dunbrack, F E Cohen
Mar 22, 2003·The Korean Journal of Internal Medicine·Mi Ran KwonSung Rok Kim

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.